Legend Biotech Corp (LEGN) stock
Close on Nov 11, 2026Market cap $3.61BP/E –Yield –
Legend Biotech Corp grew revenue 59.5% to $1.27B over the twelve months to Jun 30, 2026. Free cash flow was -$121.80M. At the latest close the market valued the company at $3.61B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $3.61B
- P/E ratio
- –
- Price to sales
- 2.84
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -3.37%
Fundamentals
- Revenue
- $1.27B
- EPS, diluted
- -$0.81
- Free cash flow
- -$121.80M
- Diluted shares
- 388M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $20.41
- Open
- $20.67
- Day's range
- $18.87 – $20.73
- Volume
- 4,417,172
- Average volume (20 days)
- 2,324,981
- Beta (5 years)
- 0.69
- 52-week range
- $16.24 – $37.50
- RSI (14 days)
- 44.6
- Volatility (1 year)
- 77.8%
- Relative volume
- 1.92×
- WACC
- 8.4%
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LEGN | S&P 500 | Difference | LEGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.9% | -2.4% | +7.4 pts | ||
| 3 months | -10.5% | -1.2% | −9.3 pts | ||
| Year to date | -10.1% | +12.3% | −22.4 pts | ||
| 1 year | -39.0% | +12.4% | −51.4 pts | ||
| 3 years | -69.7% | +78.8% | −148.5 pts | -32.8% | +21.4% |
| 5 years | -59.2% | +75.2% | −134.4 pts | -16.4% | +11.9% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Legend Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Legend Biotech
Pharmaceutical Preparations
Legend Biotech Corporation is a global biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other medical indications. Its lead commercial product is CARVYKTI (ciltacabtagene autoleucel), an autologous CAR-T cell therapy targeting B-cell maturation antigen, developed in partnership with Janssen for treating patients with relapsed or refractory multiple myeloma. In addition to cilta-cel, the company pursues an exploratory pipeline of autologous and allogeneic CAR-T and CAR-NK product candidates for solid tumors, hematologic malignancies, and autoimmune disorders. Its primary treatments serve adult cancer patients who have experienced disease progression following multiple prior lines of therapy.
Company profile, executives and historyLegend Biotech stock: common questions
What is Legend Biotech's stock price?
LEGN closed at $19.54 on Nov 11, 2026, down 4.26% on the day. Over the past 52 weeks it traded between $16.24 and $37.50.
What is Legend Biotech's market cap?
Legend Biotech was worth $3.61B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is LEGN's P/E ratio?
Legend Biotech lost money over fiscal 2025 (diluted EPS -$0.81), so it has no meaningful P/E ratio.
How much revenue does Legend Biotech make?
Legend Biotech reported revenue of $1.27B for the twelve months to Jun 30, 2026, up 59.5% from a year earlier.
Does Legend Biotech pay a dividend?
No. Legend Biotech has not paid a cash dividend over the last twelve months.
When does Legend Biotech report earnings next?
Legend Biotech is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LEGN stock performed over the past year?
Including dividends, LEGN returned -39.0% over the past year, against +12.4% for the S&P 500.
Who are Legend Biotech's competitors?
Companies most similar to Legend Biotech by business, industry and size include HCM, TGTX, INSM, LKFT, AAPG.
See a number that looks wrong?